Cetera Investment Advisers’s AbCellera Biologics ABCL Stock Holding History

Cetera Investment Advisers’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,298	Closed	-$39.4K	–	5009
2026 Q1	$39.4K	Buy	11,298 +70	+0.6%	+$252	﹤0.01%	4608
2025 Q4	$38.4K	Sell	11,228 -47	-0.4%	-$210	﹤0.01%	4537
2025 Q3	$56.7K	Sell	11,275 -2,216	-16%	-$9.77K	﹤0.01%	4415
2025 Q2	$46.3K	Sell	13,491 -763	-5%	-$1.9K	﹤0.01%	3980
2025 Q1	$31.8K	Buy	14,254 +448	+3%	+$1.28K	﹤0.01%	3893
2024 Q4	$40.5K	Sell	13,806 -71	-0.5%	-$198	﹤0.01%	3670
2024 Q3	$36.1K	Buy	+13,877	New	+$38.5K	﹤0.01%	3620
2024 Q2	–	Sell	-22,877	Closed	-$104K	–	3725
2024 Q1	$104K	Buy	+22,877	New	+$117K	﹤0.01%	3497

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Cetera Investment Advisers's ABCL Position: Q2 2026 in Review

Cetera Investment Advisers sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 11,298 shares — an estimated $39.4K sold.

Cetera Investment Advisers first reported a position in ABCL in Q1 2024 and held it in 8 quarters. The position peaked at $104K in Q1 2024. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Cetera Investment Advisers reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
Cetera Investment Advisers sold 11,298 AbCellera Biologics shares in Q2 2026, an estimated $39.4K.
Cetera Investment Advisers first reported a position in AbCellera Biologics in Q1 2024 and held it in 8 quarters.
Cetera Investment Advisers's AbCellera Biologics position peaked at $104K in Q1 2024.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.